Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Aomics GmbH logo — Aomics is a global clinical data science CRO specialising in...

Aomics GmbH

Aomics is a global clinical data science CRO specialising in delivering end-to-end clinical biometrics solutions to SMEs

Founded 2019 Germany Eschborn, Germany 4 employees Grant AI, Biotechnology +3

General Information

Company Name Aomics GmbH
Founded Year 2019
Location Germany Eschborn, Germany
Employees 4
Industries AI, Biotechnology, Health Care +2
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Aomics GmbH. To contact Aomics GmbH, visit aomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aomics GmbH compare?

A PDF of Aomics GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aomics GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Aomics GmbH

Aomics GmbH is a German startup that focuses on boosting immuno-oncology research with cost-efficient biometric solutions for SMEs. The company's slogan "Analytics-driven risk reduction in immunotherapy development" succinctly captures its mission. Aomics' approach to reducing risks in the rapidly evolving field of immunotherapy revolves around analytics-driven risk reduction powered by advanced multi-omics data analytics and specialized immuno-informatics. By integrating and analyzing diverse data sets, including genomics, transcriptomics, proteomics, and metabolomics, the company uncovers comprehensive insights into immune response mechanisms. Aomics' immuno-informatics focus allows them to predict potential immune-related adverse effects (irAEs), identify biomarkers, and optimize therapeutic strategies, ensuring that every step in the immunotherapy development process is backed by precise, data-driven decisions. This holistic approach not only accelerates the path to innovative treatments but also enhances their safety and efficacy, ultimately transforming patient outcomes. Founded in 2019, Aomics operates in the biotechnology, healthcare, and information technology industries, with its headquarters based in Germany. The company secured a grant investment on 26th August 2021. With a focus on oncology studies, they provide comprehensive statistical consulting, programming, and CDM services to support further clinical developments of new therapies. Although specific details about the investors behind the last investment round are not mentioned, Aomics GmbH's innovative approach positions it at the forefront of advancing immuno-oncology research and development.

Business keywords: Immunotherapy, Immunoinformatics, Biometrics, Bioinformatics, Clinical Development, Oncology Research, Biostatistics, Pharmacovigilance, Precision Medicine, Healthcare Data Analysis, Clinical Trials, Translational Medicine

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant - -
26 Aug 2021
Seed Round - -
15 Jun 2019

Aomics GmbH Alternatives & Competitors

View All Alternatives
Aomics GmbH vs
Avenzo Therapeutics
Avenzo Therapeutics United States

Developing the next generation of oncology therapies for patients

61 employees
Biotechnology, Health Care
Aomics GmbH vs
Aster Insights
Aster Insights United States

Accelerating oncology medical product discovery and development through our scientific and clinical...

Private Equity
78 employees
Biotechnology, Health Care
Compare Aomics GmbH vs Aster Insights
Aomics GmbH vs
Mendel.ai
Mendel.ai United States

Supercharge your clinical data workflows

Series B
167 employees
AI, Analytics
Compare Aomics GmbH vs Mendel.ai
Also compare with: Aomics GmbH vs ConcertAI ConcertAI View all alternatives

FAQ About Aomics GmbH

Aomics is a global clinical data science CRO specialising in delivering end-to-end clinical biometrics solutions to SMEs
Aomics GmbH was founded in 2019.
Aomics GmbH is headquartered in Eschborn, Germany.
Aomics GmbH operates in AI, Biotechnology, Health Care, Information Technology and Machine Learning. Its work centres on Immunotherapy, Immunoinformatics, Biometrics and Bioinformatics.
Aomics GmbH has approximately 4 employees.
Aomics GmbH has completed 2 funding rounds. The latest funding stage is Grant.
Top alternatives and competitors to Aomics GmbH include Avenzo Therapeutics, Aster Insights, Mendel.ai, Resolutum Global Pty Ltd, Scorpion Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aomics GmbH and Avenzo Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aomics GmbH, https://bouncewatch.com/company/aomics-gmbh, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes